Here's Why the Bad News About the Pfizer Vaccine Isn't So Bad

When we think of the Pfizer (NYSE:PFE) coronavirus vaccine, we think of strong performance. The company wowed the global health community when it reported overall efficacy of more than 90% in six-month follow up of its phase 3 clinical trial.

Pfizer has fully vaccinated more than 86 million Americans and is the leading vaccine provider in other countries too -- such as Israel. And speaking of Israel, the country announced news last week that paints another picture of the Pfizer vaccine's effectiveness. This may seem like bad news on the surface. But it might not be all that negative. And it actually may lead to more revenue for Pfizer. Let's take a closer look.